查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
嗜中性白血球低下症治療的全球市場 - 成長，未來展望，競爭分析(2022年～2030年)
市場調查報告書
商品編碼
1165321

嗜中性白血球低下症治療的全球市場 - 成長，未來展望，競爭分析(2022年～2030年)

Neutropenia Treatment Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030
出版日期: | 出版商: Acute Market Reports | 英文 119 Pages | 商品交期: 最快1-2個工作天內

價格

全球嗜中性白血球低下症治療的市場規模，2021年為129億7,108萬美金，從2022年到2030年的預測期間內預計以5.0％的年複合成長率成長。由於幾個原因所引起的嗜中性白血球低下症，化療後的嗜中性白血球數的減少成為主要的原因。化療因為作為白血病治療的第一選擇藥，由於白血病的盛行率增加預計嗜中性白血球低下症的病例增加。

本報告提供全球嗜中性白血球低下症治療市場相關調查，市場趨勢，競爭資訊，市場區隔分析，新興趨勢，技術分析，企業簡介等資訊。

目錄

第1章 序文

  • 報告的說明
  • 市場區隔
  • 調查手法

第2章 摘要整理

  • 市場概述:全球嗜中性白血球低下症治療市場
  • 全球嗜中性白血球低下症治療市場:各類藥物(2021年)
  • 全球嗜中性白血球低下症治療市場:各地區(2021年)
  • COVID-19影響
  • 富有魅力的投資提案:各地區(2021年)
  • 競爭分析
    • 主要的嗜中性白血球低下症治療市場供應商的市場定位
    • 嗜中性白血球低下症治療市場供應商採用的策略
    • 主要的產業策略

第3章 嗜中性白血球低下症治療市場:商務的預測與市場動態

  • 簡介
  • 全球嗜中性白血球低下症治療市場金額(2020年～2030年)
  • 市場動態
    • 推動市場要素
    • 阻礙市場要素
    • 主要課題
    • 主要的機會
  • 促進因素、阻礙因素的影響分析
  • See-Saw分析
  • 波特的五力分析

第4章 嗜中性白血球低下症治療市場:各類藥物(2020年～2030年)

  • 市場概要
  • 成長和收益分析:2021年對2030年
  • 市場區隔
    • 顆粒細胞增生因子(G-CSF)
    • 顆粒球巨噬細胞細胞聚落刺激因子(GM-CSF)
    • 抗生素
    • 抗真菌
    • 抗病毒藥

第5章 北美的嗜中性白血球低下症治療市場(2020年～2030年)

  • 市場概要
  • 嗜中性白血球低下症治療市場:各類藥物(2020年～2030年)
  • 嗜中性白血球低下症治療市場:各地區(2020年～2030年)
    • 北美

第6章 英國、歐洲聯盟的嗜中性白血球低下症治療市場(2020年～2030年)

  • 市場概要
  • 嗜中性白血球低下症治療市場:各類藥物(2020年～2030年)
  • 嗜中性白血球低下症治療市場:各地區(2020年～2030年)
    • 英國、歐洲聯盟

第7章 亞太地區的嗜中性白血球低下症治療市場(2020年～2030年)

  • 市場概要
  • 嗜中性白血球低下症治療市場:各類藥物(2020年～2030年)
  • 嗜中性白血球低下症治療市場:各地區(2020年～2030年)
    • 亞太地區

第8章 南美的嗜中性白血球低下症治療市場(2020年～2030年)

  • 市場概要
  • 嗜中性白血球低下症治療市場:各類藥物(2020年～2030年)
  • 嗜中性白血球低下症治療市場:各地區(2020年～2030年)
    • 南美

第9章 中東、非洲的嗜中性白血球低下症治療市場(2020年～2030年)

  • 市場概要
  • 嗜中性白血球低下症治療市場:各類藥物(2020年～2030年)
  • 嗜中性白血球低下症治療市場:各地區(2020年～2030年)
    • 中東、非洲

第10章 企業簡介

  • Amgen, Inc.
  • Pfizer, Inc.
  • Myelo Therapeutics, Inc.
  • Cellerant Therapeutics, Inc.
  • Sandoz(Subsidary of Novartis AG)
  • BeyondSpring Pharmaceuticals Inc.
  • Enzychem Lifesciences Corporation
  • Spectrum Pharmaceuticals, Inc.
  • Tianjin SinoBiotech Ltd.
  • S&D Pharma SK s.r.o.
  • Samsung Medical Center
  • Generon(Shanghai)Corporation Ltd.
  • PhytoHealth Corporation
  • Dong-A ST Co., Ltd.
Product Code: 138861-08-22

Neutropenia treatment accounted for a market value of US$ 12,971.08 Mn in 2021 and projected to grow at a CAGR of 5.0% during the forecast period from 2022 to 2030. In neutropenia count of neutrophil falls giving rise to compromised immunity further increasing the risk of infection. Neutropenia is observed in almost half cases of cancer patients being treated with chemotherapy but out of them most are suffering from leukaemia. According to medical experts, neutropenia can be a chronic condition because without adequate neutrophils patient become vulnerable to life-threatening infections.

Strong drug pipeline will assist the significant growth of neutropenia treatment market throughout the forecast period

Drug pipeline of neutropenia treatment is equipped with several promising drugs in phase III of clinical trials such as SPI-2012 (Spectrum Pharmaceuticals, Inc.), F-627 (Generon (Shanghai) Corporation Ltd.), Leucostim (Dong-A ST Co., Ltd.), myelo001 (Myelo Therapeutics, Inc.), Plinabulin (BeyondSpring Pharmaceuticals Inc.), and Romyelocel-L (Cellerant Therapeutics, Inc.). Neutropenia caused due to several causes major being the post-chemotherapy decrease in count of neutrophils. Increasing prevalence of leukemia expected to rise the neutropenia cases as chemotherapy being the first-line of treatment for leukemia. However, precautionary treatment regimen is ready to avoid effect of neutropenia-based infections with antibacterial, antiviral and antifungal drugs.

North America dominated the overall global market specifically due to promising drug pipeline, and developed diagnostic landscape

In 2021, North America dominated the market and expected to retain its position throughout the forecast period due to rising awareness related to neutropenia, increasing prevalence of side effects related to chemotherapy during leukemia treatment, and high expectation from drugs in pipeline. According to several studies, the prevalence of neutropenia is around 4.4% and expected to increase in specific regions with rising prevalence of leukemia. During the forecast period from 2019 to 2027, Asia Pacific will grow gradually due to increasing awareness related to neutropenia diagnosis & treatment coupled with developing diagnostic technologies in rare disease sector.

The key companies included in the neutropenia treatment industry analyzed based on financial data, product portfolio, current press releases, and major market strategies. This report also includes attractive investment proposition studied based on exclusive geographical PESTEL analysis. Major companies included in the report are Amgen, Inc., Spectrum Pharmaceuticals, Inc., Generon (Shanghai) Corporation Ltd., Dong-A ST Co., Ltd., BeyondSpring Pharmaceuticals Inc., Myelo Therapeutics, Inc., Cellerant Therapeutics, Inc., and Sandoz (Subsidiary of Novartis AG) among others.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Neutropenia Treatment market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Neutropenia Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Drug Class

  • Granulocyte-colony stimulating factor (G-CSF)
  • Granulocyte-macrophage colony-stimulating factor (GM-CSF)
  • Antibiotics
  • Antifungal
  • Antiviral

Region Segment (2020-2030; US$ Million)

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • UK and European Union
    • UK
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Africa
    • Rest of Middle East and Africa

Global Impact of COVID-19 Segment (2020-2021; US$ Million )

  • Pre COVID-19 situation
  • Post COVID-19 situation

Key questions answered in this report:

  • What are the key micro and macro environmental factors that are impacting the growth of Neutropenia Treatment market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2030.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Neutropenia Treatment market?
  • Which is the largest regional market for Neutropenia Treatment market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Neutropenia Treatment market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Neutropenia Treatment market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Neutropenia Treatment Market
  • 2.2. Global Neutropenia Treatment Market, By Drug Class, 2021 (US$ Million)
  • 2.3. Global Neutropenia Treatment Market, By Geography, 2021 (US$ Million)
  • 2.4. Impact of Covid 19
  • 2.5. Attractive Investment Proposition by Geography, 2021
  • 2.6. Competitive Analysis
    • 2.6.1. Market Positioning of Key Neutropenia Treatment Market Vendors
    • 2.6.2. Strategies Adopted by Neutropenia Treatment Market Vendors
    • 2.6.3. Key Industry Strategies

3. Neutropenia Treatment Market: Business Outlook & Market Dynamics

  • 3.1. Introduction
  • 3.2. Global Neutropenia Treatment Market Value, 2020 - 2030, (US$ Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers
    • 3.3.2. Market Restraints
    • 3.3.3. Key Challenges
    • 3.3.4. Key Opportunities
  • 3.4. Impact Analysis of Drivers and Restraints
  • 3.5. See-Saw Analysis
  • 3.6. Porter's Five Force Model
    • 3.6.1. Supplier Power
    • 3.6.2. Buyer Power
    • 3.6.3. Threat Of Substitutes
    • 3.6.4. Threat Of New Entrants
    • 3.6.5. Competitive Rivalry
  • 3.7. PESTEL Analysis
    • 3.7.1. Political Landscape
    • 3.7.2. Economic Landscape
    • 3.7.3. Technology Landscape
    • 3.7.4. Legal Landscape
    • 3.7.5. Social Landscape

4. Neutropenia Treatment Market: By Drug Class, 2020-2030, USD (Million)

  • 4.1. Market Overview
  • 4.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 4.3. Market Segmentation
    • 4.3.1. Granulocyte-colony stimulating factor (G-CSF)
    • 4.3.2. Granulocyte-macrophage colony-stimulating factor (GM-CSF)
    • 4.3.3. Antibiotics
    • 4.3.4. Antifungal
    • 4.3.5. Antiviral

5. North America Neutropenia Treatment Market, 2020-2030, USD (Million)

  • 5.1. Market Overview
  • 5.2. Neutropenia Treatment Market: By Drug Class, 2020-2030, USD (Million)
  • 5.3.Neutropenia Treatment Market: By Region, 2020-2030, USD (Million)
    • 5.3.1.North America
      • 5.3.1.1. U.S.
      • 5.3.1.2. Canada
      • 5.3.1.3. Rest of North America

6. UK and European Union Neutropenia Treatment Market, 2020-2030, USD (Million)

  • 6.1. Market Overview
  • 6.2. Neutropenia Treatment Market: By Drug Class, 2020-2030, USD (Million)
  • 6.3.Neutropenia Treatment Market: By Region, 2020-2030, USD (Million)
    • 6.3.1.UK and European Union
      • 6.3.1.1. UK
      • 6.3.1.2. Germany
      • 6.3.1.3. Spain
      • 6.3.1.4. Italy
      • 6.3.1.5. France
      • 6.3.1.6. Rest of Europe

7. Asia Pacific Neutropenia Treatment Market, 2020-2030, USD (Million)

  • 7.1. Market Overview
  • 7.2. Neutropenia Treatment Market: By Drug Class, 2020-2030, USD (Million)
  • 7.3.Neutropenia Treatment Market: By Region, 2020-2030, USD (Million)
    • 7.3.1.Asia Pacific
      • 7.3.1.1. China
      • 7.3.1.2. Japan
      • 7.3.1.3. India
      • 7.3.1.4. Australia
      • 7.3.1.5. South Korea
      • 7.3.1.6. Rest of Asia Pacific

8. Latin America Neutropenia Treatment Market, 2020-2030, USD (Million)

  • 8.1. Market Overview
  • 8.2. Neutropenia Treatment Market: By Drug Class, 2020-2030, USD (Million)
  • 8.3.Neutropenia Treatment Market: By Region, 2020-2030, USD (Million)
    • 8.3.1.Latin America
      • 8.3.1.1. Brazil
      • 8.3.1.2. Mexico
      • 8.3.1.3. Rest of Latin America

9. Middle East and Africa Neutropenia Treatment Market, 2020-2030, USD (Million)

  • 9.1. Market Overview
  • 9.2. Neutropenia Treatment Market: By Drug Class, 2020-2030, USD (Million)
  • 9.3.Neutropenia Treatment Market: By Region, 2020-2030, USD (Million)
    • 9.3.1.Middle East and Africa
      • 9.3.1.1. GCC
      • 9.3.1.2. Africa
      • 9.3.1.3. Rest of Middle East and Africa

10. Company Profile

  • 10.1. Amgen, Inc.
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Portfolio
    • 10.1.4. Strategic Initiatives
  • 10.2. Pfizer, Inc.
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Portfolio
    • 10.2.4. Strategic Initiatives
  • 10.3. Myelo Therapeutics, Inc.
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Portfolio
    • 10.3.4. Strategic Initiatives
  • 10.4. Cellerant Therapeutics, Inc.
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Portfolio
    • 10.4.4. Strategic Initiatives
  • 10.5. Sandoz (Subsidary of Novartis AG)
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Portfolio
    • 10.5.4. Strategic Initiatives
  • 10.6. BeyondSpring Pharmaceuticals Inc.
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Portfolio
    • 10.6.4. Strategic Initiatives
  • 10.7. Enzychem Lifesciences Corporation
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Portfolio
    • 10.7.4. Strategic Initiatives
  • 10.8. Spectrum Pharmaceuticals, Inc.
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Portfolio
    • 10.8.4. Strategic Initiatives
  • 10.9. Tianjin SinoBiotech Ltd.
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Portfolio
    • 10.9.4. Strategic Initiatives
  • 10.10. S&D Pharma SK s.r.o.
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Portfolio
    • 10.10.4. Strategic Initiatives
  • 10.11. Samsung Medical Center
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Product Portfolio
    • 10.11.4. Strategic Initiatives
  • 10.12. Generon (Shanghai) Corporation Ltd.
    • 10.12.1. Company Overview
    • 10.12.2. Financial Performance
    • 10.12.3. Product Portfolio
    • 10.12.4. Strategic Initiatives
  • 10.13. PhytoHealth Corporation
    • 10.13.1. Company Overview
    • 10.13.2. Financial Performance
    • 10.13.3. Product Portfolio
    • 10.13.4. Strategic Initiatives
  • 10.14. Dong-A ST Co., Ltd.
    • 10.14.1. Company Overview
    • 10.14.2. Financial Performance
    • 10.14.3. Product Portfolio
    • 10.14.4. Strategic Initiatives

List of Tables

  • TABLE 1 Global Neutropenia Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 2 North America Neutropenia Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 3 UK and European Union Neutropenia Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 4 Asia Pacific Neutropenia Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 5 Latin America Neutropenia Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 6 Middle East and Africa Neutropenia Treatment Market By Drug Class, 2020-2030, USD (Million)

List of Figures

  • FIG. 1 Global Neutropenia Treatment Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Neutropenia Treatment Market: Quality Assurance
  • FIG. 5 Global Neutropenia Treatment Market, By Drug Class, 2021
  • FIG. 6 Global Neutropenia Treatment Market, By Geography, 2021
  • FIG. 7 Global Neutropenia Treatment Market, By Drug Class, 2021 Vs 2030, %
  • FIG. 8 U.S. Neutropenia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 9 Canada Neutropenia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 10 Rest of North America Neutropenia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 11 UK Neutropenia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 12 Germany Neutropenia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 13 Spain Neutropenia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 14 Italy Neutropenia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 15 France Neutropenia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 16 Rest of Europe Neutropenia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 17 China Neutropenia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 18 Japan Neutropenia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 19 India Neutropenia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 20 Australia Neutropenia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 21 South Korea Neutropenia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 22 Rest of Asia Neutropenia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 23 Brazil Neutropenia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 24 Mexico Neutropenia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 25 Rest of Latin America Neutropenia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 26 GCC Neutropenia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 27 Africa Neutropenia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 28 Rest of Middle East and Africa Neutropenia Treatment Market (US$ Million), 2020 - 2030